CDKN2A Alterations and Response to Immunotherapy in Solid Tumors.

ABSTRACT:

Purpose

Immune checkpoint inhibitors (ICI) have shown clinical benefit in many types of metastatic cancers with only a few predictive biomarkers identified so far. CDKN2A is commonly altered in human cancers, but prior studies have provided conflicting evidence regarding the association between CDKN2A genomic alterations (GA) and response to ICIs. Herein, we examined the impact of loss-of-function CDKN2A alterations on response and survival in patients treated with ICIs.

Experimental design

We studied the association between loss-of-function CDKN2A alterations and the response to ICIs in two independent cohorts of six different cancer types. Seven hundred and eighty-nine patients treated at Dana-Farber Cancer Institute (DFCI; Boston, MA) and 1,250

SUBMITTER: Adib E 

PROVIDER: S-EPMC8900067 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature